If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-14. Numbers and descriptions here follow the published literature rather than marketing material.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
== S == Saegusa–Ito oxidation Sakurai reaction Salol reaction Sandheimer Sandmeyer diphenylurea isatin synthesis Sandmeyer isonitrosoacetanilide isatin synthesis Sandmeyer reaction Sanger reagent Saponification Sarett oxidation Schiemann reaction Schiff reaction Schiff test Schlenk equilibrium Schlosser modification Schlosser variant Schmidlin ketene synthesis Schmidt degradation Schmidt reaction Scholl reaction Schorigin Shorygin reaction, Shorygin reaction, Wanklyn reaction Schotten–Baumann reaction Seliwanoff's test Semidine rearrangement Semmler–Wolff reaction Seyferth–Gilbert homologation Shapiro reaction Sharpless asymmetric dihydroxylation Sharpless epoxidation Sharpless oxyamination or aminohydroxylation Shenck ene reaction Shi epoxidation Shiina esterification Shiina macrolactonization or Shiina lactonization Sigmatropic reaction Simmons–Smith reaction Simonini reaction Simonis chromone cyclization Simons process Skraup chinolin synthesis Skraup reaction Smiles rearrangement SNAr nucleophilic aromatic substitution SN1 SN2 SNi Solvolysis Sommelet reaction Sonn–Müller method Sonogashira coupling Sørensen formol titration Staedel–Rugheimer pyrazine synthesis Stahl oxidation Staudinger reaction Staudinger synthesis Steglich esterification Stephen aldehyde synthesis Stetter reaction Stevens rearrangement Stieglitz rearrangement Stille coupling Stobbe condensation Stollé synthesis Stork acylation Stork enamine alkylation Strecker amino acid synthesis Strecker degradation Strecker sulfite alkylation Strecker synthesis Stereocontrolled 1,2-addition to carbonyl groups Suzuki coupling Swain equation Swarts reaction Swern oxidation
=== Overdose === Overdosage may result in vomiting, sedation, disturbances in heart rhythm, dizziness, sweating, nausea, tremors, and rarely amnesia, confusion, coma, or convulsions. Overdose deaths have occurred, sometimes involving other drugs, but also with citalopram as the sole agent. Citalopram and N-desmethylcitalopram may be quantified in blood or plasma to confirm a diagnosis of poisoning in hospitalized patients or to assist in a medicolegal death investigation. Blood or plasma citalopram concentrations are usually in a range of 50-400 μg/L in persons receiving the drug therapeutically, 1000–3000 μg/L in patients who survive acute overdosage, and 3–30 mg/L in those who do not survive. It is the most dangerous of SSRIs in overdose.
An amino acid neurotransmitter is an amino acid which is able to transmit a nerve message across a synapse. Neurotransmitters (chemicals) are packaged into vesicles that cluster beneath the axon terminal membrane on the presynaptic side of a synapse in a process called endocytosis. Amino acid neurotransmitter release (exocytosis) is dependent upon calcium Ca2+ and is a presynaptic response.
Pulmonary disease: Pathophysiology: Due to vascular congestion in the lung, the pulmonary artery (Figure 3) becomes dilated and can compress the aorta and the LRLN. Primary pulmonary hypertension Pulmonary emboli Malignancy (pulmonary, mediastinal) Autoimmune: Mixed connective tissue disease Notable case: A young female with a history of mixed connective tissue disease presented with hoarseness of voice and was found to have secondary pulmonary artery hypertension. This was causing right heart enlargement and therefore compression of the LRLN. Idiopathic
The GIUK gap (sometimes written G-I-UK) is an area in the northern Atlantic Ocean that forms a naval choke point. Its name is an initialism for Greenland, Iceland, and the United Kingdom, the gap being the two stretches of open ocean among these three landmasses. It separates the Norwegian Sea and the North Sea from the open Atlantic Ocean. The term is typically used in relation to military topics. The area has been considered strategically important since the beginning of the 20th century.
Sources: en.wikipedia.org
== Products == ROSE-010 is a pharmaceutical therapy intended to treat pain symptoms of irritable bowel syndrome. The pharmaceutical, ROSE-010 mimics the hormone GLP-1 which modulates smooth muscle contractions and thus reduces spasms associated with IBS. ROSE-010 must be administered subcutaneously or intravenously. A phase II double-blinded placebo controlled trial in Europe demonstrated efficacy of this approach, and a phase I/II trial in the US established the safety of this concept also in IBS patients with predominant constipation. These clinical data, together with the preclinical data generated by Rose Pharma, provide the rationale for this peptide hormone based therapy for acute pain attacks in IBS.
The top three single agent/disease killers are HIV/AIDS, TB and malaria. While the number of deaths due to nearly every disease have decreased, deaths due to HIV/AIDS have increased fourfold. Childhood diseases include pertussis, poliomyelitis, diphtheria, measles and tetanus. Children also make up a large percentage of lower respiratory and diarrheal deaths. In 2012, approximately 3.1 million people have died due to lower respiratory infections, making it the number 4 leading cause of death in the world.
In May 2023, Ajinomoto signed a letter of intent for a strategic alliance with Solar Foods, a company that developed Solein, a microbial protein feeding on CO2 as a nutrient source, and obtained a marketing license in Singapore. In November 2023, Ajinomoto acquired US-based Forge Biologics for $620 million. In September 2024, Ajinomoto entered into a global strategic partnership with Danone to reduce greenhouse gas emissions from Danone’s raw milk supply chain. In the same year, through joint research with Professor Chinatsu Kasamatsu (Project Professor) of the Institute for SDGs Promotion at Ochanomizu University in Japan, Ajinomoto became the first in the world to develop a new concept of 'electric seasoning,' which adjusts the taste of food using transdermal electrical stimulation. In March 2025, Ajinomoto decided to participate as a partner in the 'Demonstration Survey for the Restoration Model of Degraded Agricultural Land in Brazil,' a project under the Japan-Brazil Green Partnership Initiative promoted by the governments of Japan and Brazil. In April 2025, Ajinomoto was selected by CDP, an international environmental not-for-profit charity, for its "Climate Change A-List" for fiscal 2024. This is the fifth consecutive year that Ajinomoto has been selected for the A-list.
Enantiomers of a chiral drug often interact in an enantioselective way in a chiral environment. This may be offered by different biotic substances (viz. proteins, nucleic acids, phospholipids and oligosaccharides). They are made up of chiral building blocks that are put together in space in handed conformations. These biological targets function as receptors for the drug enantiomers. So, at the binding sites of these receptors, enantiomers will be seen as different chemical species. The three point attachment model (Easson & Stedman model) can be used to see how chiral discrimination works. Figure depicts how the enantiomers of a drug interact with receptors in a way that depends on the drug's shape. This model was made for chiral drugs with a single stereogenic center. It says that there are three binding sites in the receptor (B', C' and D') that match the drug's pharmacophoric groups (B, C, D). A three-point fit (good fit) is possible for the eutomer at BB', CC' and DD'(Fig. A). Even though the distomer is the wrong enantiomer, it can fit either a one-point interaction (bad fit), or a two-point attachment (CC' and DD') with the same receptor site as shown in (Fig. B). Eutomer is the version that works the way you want it to, and distomer is the version that doesn't work or works in a way you don't want it to. Most of the time, the mirror-image versions have different binding affinities. In the eutomer, the ligands or moiety around a stereogenic element have more binding energy than in the distomer.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.